Clinical Trial Update: Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating the combination of sintilimab and bevacizumab with chemotherapy for triple-negative breast cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING